FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC
ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.
How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap
Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.
How Can Oncology Staffing Shortages Be Remedied?
Manali Patel, MD, MPH, MS, FASCO, discusses current gaps, projected needs, and actionable strategies for the US hematology and medical oncology workforce.
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.
Forming CUTNETs: A Joint Venture Between Surgery and Oncology in NETs
Considering historical trends of underpowered data in NET surgical studies, CUTNETs established a collaboration of surgical teams to better power research.
Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer
Phase 3 data demonstrate PD-L1 positivity and BRCA mutation status as prognostic for improved overall survival regardless of treatment arm.
